There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ:LEGN) stands ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

This fun logo quiz features five challenging rounds, and includes themed rounds on car logos, food companies and fashion brands. If there’s one thing lockdown taught us, it was that quizzes were a ...

Legend Biotech Corp (LEGN) reports significant sales growth for CARVYKTI, despite facing increased expenses and a net loss in Q3 2024. Although the revenue and EPS for Legend Biotech (LEGN ...

To date, more than 2,000 patients have been treated with Carvykti worldwide, and the overall benefit-risk profile of Carvykti remains favourable." Autolus has picked up its first product approval ...

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial.

At a Case-Based Roundtable event, Al’Hadidi moderated a discussion on when to use ciltacabtagene autoleucel (cilta-cel; Carvykti) now that it has been approved in the second line. He said other ...

21 November 2024 Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care.